Pfizer’s Inflectra, Takeda’s Entyvio, and Janssen’s Simponi Projected to Gain Ground in the Increasingly Competitive Ulcerative Colitis Market

According to the latest quarterly update from Spherix Global Insights, US gastroenterologists are gearing up for near term change Download Report Overview EXTON, Pa., July 7, 2017 /PRNewswire/ -- Results from a recent study just released by Spherix Global Insights reveal that US gastroenterologists (n=103) project significant growth of Takeda's Entyvio, Janssen's Simponi, and Pfizer/Hospira's [...]

BMS’ Orencia Plunges into the Fray of Battle for Alternative MOA for Psoriatic Arthritis with Recent FDA Approval…. Can it Find a Unique Space to Play?

Approval of Orencia for Psoriatic Arthritis (PsA) opens door for expansion of use based on existing off-label experience, adding further challenge to Novartis's Cosentyx and Janssen's Stelara for preferred TNF alternative, according to recent reports from Spherix Global Insights. Download Report Overview EXTON, Pa., July 6, 2017 /PRNewswire/ -- BMS' Orencia, already indicated for Rheumatoid [...]

In the Race for Alternative MOA Biologic in Crohn’s Disease, Takeda’s Entyvio Maintains the Lead, but Janssen’s Stelara is Gaining Fast

Not only has Stelara's user-base substantially increased since Q1, but US gastroenterologists (n=103) are projecting significant gains for the IL-12/23 inhibitor over the next six months. Download Report Overview EXTON, Pa., June 27, 2017 /PRNewswire/ -- Spherix Global Insights has just released the second quarter results of an independent survey regarding the evolving practice patterns [...]

Janssen’s Stelara overtakes Takeda’s Entyvio as the leading alternative MOA in Crohn’s Disease, but pressure is on to maximize IBD value in advance of pipeline drugs from Celgene (mongersen, ozanimod), Roche/Genentech (etrolizumab) and Pfizer (Xeljanz)

According to RealWorld Dynamix: Biologic Switching in IBD, an annual patient chart analysis conducted by Spherix Global Insights, biologic use in IBD is becoming increasingly dynamic, with switching rates up significantly in both Ulcerative Colitis (UC) and Crohn's Disease (CD) compared to 2016. Furthermore, switching patterns have changed dramatically with the recent introduction of Stelara. [...]